TY - JOUR
T1 - North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
AU - Alhusayen, Raed
AU - Dienes, Serena
AU - Lam, Megan
AU - Alavi, Afsaneh
AU - Alikhan, Ali
AU - Aleshin, Maria
AU - Bahashwan, Emad
AU - Daveluy, Steve
AU - Goldfarb, Noah
AU - Garg, Amit
AU - Gulliver, Wayne
AU - Jaleel, Tarannum
AU - Kimball, Alexa B.
AU - Kirchhof, Mark G.
AU - Kirby, Joslyn
AU - Lenczowski, Joi
AU - Lev-Tov, Hadar
AU - Lowes, Michelle A.
AU - Lara-Corrales, Irene
AU - Micheletti, Robert
AU - Okun, Martin
AU - Orenstein, Lauren
AU - Poelman, Susan
AU - Piguet, Vincent
AU - Porter, Martina
AU - Resnik, Barry
AU - Sibbald, Cathryn
AU - Shi, Vivian
AU - Sayed, Christopher
AU - Wong, Se Mang
AU - Zaenglein, Andrea
AU - Veillette, Helene
AU - Hsiao, Jennifer L.
AU - Naik, Haley B.
N1 - Publisher Copyright:
© 2025 American Academy of Dermatology, Inc.
PY - 2025/4
Y1 - 2025/4
N2 - Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Methods: Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. Results: One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.
AB - Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Methods: Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. Results: One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.
UR - http://www.scopus.com/inward/record.url?scp=85215584269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215584269&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2024.11.071
DO - 10.1016/j.jaad.2024.11.071
M3 - Article
C2 - 39725212
AN - SCOPUS:85215584269
SN - 0190-9622
VL - 92
SP - 825
EP - 852
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -